A Phase III, Randomized, Double-Blinded, Placebo-Controlled, Multi-Center Study to Evaluate the Immunogenicity, Safety and Tolerability of CSL Limited Inactivated Influenza Vaccine in Adults Greater Than or Equal to 18 to Less Than 65 Years of Age

Trial Profile

A Phase III, Randomized, Double-Blinded, Placebo-Controlled, Multi-Center Study to Evaluate the Immunogenicity, Safety and Tolerability of CSL Limited Inactivated Influenza Vaccine in Adults Greater Than or Equal to 18 to Less Than 65 Years of Age

Completed
Phase of Trial: Phase III

Latest Information Update: 11 Sep 2008

At a glance

  • Drugs Influenza virus vaccine (Afluria) (Primary)
  • Indications Influenza virus infections
  • Focus Adverse reactions; Pharmacodynamics
  • Most Recent Events

    • 11 Sep 2008 Last checked against ClinicalTrials.gov record.
    • 03 Sep 2008 Results formed the basis of the licensing application, which was approved by the US FDA in September 2007, according to a CSL media release.
    • 29 Jul 2008 Secondary endpoint 'Haemagglutin inhibition antibody levels' has been met.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top